Insider Selling: United Therapeutics Corp. CEO Sells 3,833 Shares of Stock (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine Rothblatt sold 3,833 shares of United Therapeutics Corp. stock in a transaction that occurred on Thursday, January 9th. The shares were sold at an average price of $108.35, for a total value of $415,305.55. Following the completion of the transaction, the chief executive officer now directly owns 140 shares of the company’s stock, valued at approximately $15,169. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
UTHR has been the subject of a number of recent research reports. Analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note to investors on Tuesday, December 31st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Separately, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note to investors on Tuesday, December 24th. They now have a “hold” rating on the stock. Finally, analysts at Ladenburg Thalmann upgraded shares of United Therapeutics Corp. from a “neutral” rating to a “buy” rating in a research note to investors on Monday, December 23rd. They now have a $138.00 price target on the stock. Nine analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. United Therapeutics Corp. currently has an average rating of “Hold” and a consensus price target of $88.21.
United Therapeutics Corp. (NASDAQ:UTHR) traded down 0.88% during mid-day trading on Thursday, hitting $108.74. The stock had a trading volume of 710,203 shares. United Therapeutics Corp. has a 52-week low of $51.38 and a 52-week high of $116.65. The stock’s 50-day moving average is $97.77 and its 200-day moving average is $82.03. The company has a market cap of $5.462 billion and a price-to-earnings ratio of 19.93.
United Therapeutics Corp. (NASDAQ:UTHR) last released its earnings data on Tuesday, October 29th. The company reported $2.98 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.59 by $1.39. The company had revenue of $302.20 million for the quarter, compared to the consensus estimate of $279.02 million. During the same quarter last year, the company posted $2.82 earnings per share. United Therapeutics Corp.’s revenue was up 24.6% compared to the same quarter last year. On average, analysts predict that United Therapeutics Corp. will post $5.45 earnings per share for the current fiscal year.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.